FDA Approves Darzalex Faspro (daratumumab and hyaluronidase-fihj) in Combination with Velcade (bortezomib), Revlimid (lenalidomide), and Dexamethasone for Transplant-Eligible, Newly Diagnosed Multiple Myeloma Patients (https://www.myeloma.org/news-events/multiple-myeloma-news/fda-approves-darzalex-faspro-plus-VRd)